Raymond James Financial’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Raymond James Financial's ACAD Position: Q3 2026 in Review
Raymond James Financial increased its Acadia Pharmaceuticals (ACAD) stake by 68% in Q3 2026, buying an estimated $1.83M and bringing the position to 168,424 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3099.
Raymond James Financial first reported a position in ACAD in Q4 2024 and has held it in 8 quarters since. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Raymond James Financial held 168,424 shares of Acadia Pharmaceuticals worth $3.39M as of Q3 2026.
- Raymond James Financial bought 68,330 Acadia Pharmaceuticals shares in Q3 2026, an estimated $1.83M.
- Acadia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3099 holding.
- Raymond James Financial first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.